6OP.F OSE IMMUNOTHERAPE.EO -20

Healthcare Biotechnology Frankfurt Exchange
1.68 EUR
Close of Nov 11, 2026
1.65 6.02
Market cap
EUR 41.5M
P/E
-
P/B
1.47x
ROE
-135.8%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the fiscal year ending Dec 2025.

Is 6OP.F undervalued?

Graham number

The Graham number of OSE IMMUNOTHERAPE.EO -20 cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

OSE IMMUNOTHERAPE.EO -20 fundamental analysis

No fundamental analysis for OSE IMMUNOTHERAPE.EO -20 yet.

OSE IMMUNOTHERAPE.EO -20 stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About OSE IMMUNOTHERAPE.EO -20

OSE Immunotherapeutics SA, a clinical-stage biotechnology company, develops immunotherapies in the areas of immune-oncology and immune-inflammation in France and internationally. The company's products include Tedopi that is in Phase III clinical trial for the treatment of non-small cell lung cancer, as well as in Phase II clinical trial to pancreatic and ovarian cancer; OSE-279, which is in a Phase I/II clinical trial in patients with advanced solid tumors or lymphomas; OSE…

Full company profile